General Partner
CurrentHealthcare-focused investment firm founded in 1991, with our Frazier Life Sciences (FLS) team focused on investing in and building companies developing novel therapeutics. Investing out of FLS XI, a $987M venture fund raised in 2022, and FLS PF, a >$800M evergreen vehicle for publics and crossover investments.* Current Boards: Hummingbird Bioscience.